Pancreatic Cancer Drug Daraxonrasib (Rasonque): FDA Approval, Survival Data, Cost and New First-Line Results

Pancreatic Cancer Drug Daraxonrasib

The pancreatic cancer drug daraxonrasib is now FDA-approved and sold in the U.S. as Rasonque. The agency approved it on August 26, 2026 for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or can’t receive multiagent systemic therapy. In the pivotal trial, patients lived a median of 13.2 months … Read more